Gemtuzumab
Acute Myeloblastic Leukemia
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 4 / ApprovedActive
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 72/ 100
- Competitive Position
- 95/ 100
Competitive context
684 Active assets in the Acute Myeloblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BBB |
AMSACRINE University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-VINCRISTINE Janssen Research & Development, LLC | Phase 3 | BBB |
ETOPOSIDE Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 3 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →